Understanding risk and refining surveillance following tumor resection for low grade non-muscle invasive bladder cancer.
作者信息
Peyton Charles C, Azizi Mounsif, Sexton Wade J
机构信息
Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
出版信息
Transl Androl Urol. 2018 Dec;7(6):987-989. doi: 10.21037/tau.2018.07.07.
Abstract
摘要
相似文献
1
Understanding risk and refining surveillance following tumor resection for low grade non-muscle invasive bladder cancer.
Transl Androl Urol. 2018 Dec;7(6):987-989. doi: 10.21037/tau.2018.07.07.
2
[Should we propose a systematic second transurethral resection of the bladder for all high-risk non-muscle invasive bladder cancers?].
Prog Urol. 2014 Sep;24(10):640-5. doi: 10.1016/j.purol.2014.03.006. Epub 2014 Apr 29.
3
[Repeat transurethral resection for non-muscle invasive bladder cancer].
Zhonghua Wai Ke Za Zhi. 2009 May 15;47(10):725-7.
4
Repeated transurethral resection for non-muscle invasive bladder cancer.
Int J Clin Exp Med. 2015 Jan 15;8(1):1416-9. eCollection 2015.
5
[The intravesical recurrence after 3-day consecutive intravesical instillation of pirarubicine hydrochloride (THP) following transurethral resection of bladder tumor (TURBT) for non-muscle-invasive bladder cancer].
Nihon Hinyokika Gakkai Zasshi. 2012 Jul;103(4):610-6. doi: 10.5980/jpnjurol.103.610.
6
Shorter recurrence-free survival time, higher risk of multiple recurrences: a retrospective study of non-muscle invasive bladder cancer after transurethral resection.
Chin Med J (Engl). 2012 Oct;125(20):3681-6.
7
Clinical outcomes of second transurethral resection in non-muscle invasive high-grade bladder cancer: a retrospective, multi-institutional, collaborative study.
Int J Clin Oncol. 2017 Apr;22(2):353-358. doi: 10.1007/s10147-016-1048-z. Epub 2016 Oct 15.
8
Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
Arch Ital Urol Androl. 2017 Dec 31;89(4):272-276. doi: 10.4081/aiua.2017.4.272.
9
Active surveillance for low-risk bladder cancer.
Urol Oncol. 2014 Jan;32(1):33.e7-10. doi: 10.1016/j.urolonc.2012.12.003. Epub 2013 Mar 19.
10
Pathological Outcomes for Patients Who Failed To Remain Under Active Surveillance for Low-risk Non-muscle-invasive Bladder Cancer: Update and Results from the Bladder Cancer Italian Active Surveillance Project.
Eur Urol Oncol. 2018 Oct;1(5):437-442. doi: 10.1016/j.euo.2018.05.006. Epub 2018 Jun 5.
本文引用的文献
1
Conditional analyses of recurrence and progression in patients with TaG1 non-muscle-invasive bladder cancer.
Urol Oncol. 2018 May;36(5):238.e19-238.e27. doi: 10.1016/j.urolonc.2018.01.017. Epub 2018 Mar 3.
2
Implementing risk-aligned bladder cancer surveillance care.
Urol Oncol. 2018 May;36(5):257-264. doi: 10.1016/j.urolonc.2017.12.016. Epub 2018 Feb 13.
3
The Burden of Cystoscopic Bladder Cancer Surveillance: Anxiety, Discomfort, and Patient Preferences for Decision Making.
Urology. 2017 Oct;108:122-128. doi: 10.1016/j.urology.2017.07.016. Epub 2017 Jul 21.
4
Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
Urol Oncol. 2016 Oct;34(10):460-8. doi: 10.1016/j.urolonc.2016.05.028. Epub 2016 Jun 29.
5
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
Eur Urol. 2017 Mar;71(3):447-461. doi: 10.1016/j.eururo.2016.05.041. Epub 2016 Jun 17.
6
Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline.
J Urol. 2016 Oct;196(4):1021-9. doi: 10.1016/j.juro.2016.06.049. Epub 2016 Jun 16.
7
Dynamic Prognostication Using Conditional Recurrence and Progression Estimates for Patients with Nonmuscle Invasive Bladder Cancer.
J Urol. 2016 Jul;196(1):46-51. doi: 10.1016/j.juro.2016.01.102. Epub 2016 Feb 2.
8
Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group.
J Clin Oncol. 2016 Jun 1;34(16):1935-44. doi: 10.1200/JCO.2015.64.4070. Epub 2016 Jan 25.
9
Cancer statistics, 2015.
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5.
10
Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer.
J Urol. 2014 Aug;192(2):305-15. doi: 10.1016/j.juro.2014.02.2573. Epub 2014 Mar 25.
Zotero 插件